health
Former Sen. Ben Sasse shines the spotlight on a possible breakthrough for pancreatic cancer
Former Sen. Ben Sasse is taking Revolution Medicines' daraxonrasib, which has shown promise as a treatment for pancreatic cancer.
TL;DR
- Revolution Medicines is awaiting Phase 3 trial results for its experimental drug, daraxonrasib, a potential targeted treatment for pancreatic cancer.
- Pancreatic cancer has a low five-year survival rate, and existing treatments have seen limited improvement.
- Former Sen. Ben Sasse revealed he is taking daraxonrasib for Stage 4 pancreatic cancer, reporting significant tumor shrinkage but also severe side effects like a rash.
- Daraxonrasib targets RAS mutations, which are common in pancreatic cancer, but its broad action causes side effects due to RAS proteins being present throughout the body.
- The U.S. FDA requires Revolution Medicines to demonstrate that daraxonrasib extends overall survival, not just shrinks tumors, for approval.
- Analysts predict a significant stock increase if the drug shows a survival benefit of over 13 months, with acquisition by larger pharmaceutical companies also being a possibility.
- Despite speculation, Revolution Medicines' CEO states the company is focused on developing the drug and making a difference.